Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group.
about
Why prevent, diagnose and treat congenital toxoplasmosis?Toxoplasma histone acetylation remodelers as novel drug targetsManagement of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings)Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study GroupDrug repurposing and human parasitic protozoan diseasesCrystal structure of adenosine kinase from Toxoplasma gondii at 1.8 Å resolutionToxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitorsCrystal structures of Toxoplasma gondii HGXPRTase reveal the catalytic role of a long flexible loopSynergistic effect of clindamycin and atovaquone in acute murine toxoplasmosisActivity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondiiRifabutin is active in murine models of toxoplasmosisActivity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosisEffects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in miceEvaluation of the effect of pyrimethamine, an anti-malarial drug, on HIV-1 replicationDrug treatment of toxoplasmic encephalitis in acquired immunodeficiency syndrome.Toxoplasma gondii infection in Kyrgyzstan: seroprevalence, risk factor analysis, and estimate of congenital and AIDS-related toxoplasmosisRepurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica[Magnetic resonance spectroscopy for inflammatory brain diseases].Alternative treatment approach to cerebral toxoplasmosis in HIV/AIDS: experience from a resource-poor setting.Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence.The new macrolides. Azithromycin and clarithromycin.The role of DNA microarrays in Toxoplasma gondii research, the causative agent of ocular toxoplasmosis.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerPenetration of clindamycin and its metabolite N-demethylclindamycin into cerebrospinal fluid following intravenous infusion of clindamycin phosphate in patients with AIDS.Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycinDisposition of intravenous pyrimethamine in healthy volunteers.In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductaseImmune CD8(+) T cells prevent reactivation of Toxoplasma gondii infection in the immunocompromised host.Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy.Antiparasitic agent atovaquoneIdentification of small-molecule inhibitors of nucleoside triphosphate hydrolase in Toxoplasma gondii.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theAcute Confusional State: A Manifestation of Toxoplasma and CMV Co-infection in HIV Patient.Central nervous system infection during immunosuppression.Trends, productivity losses, and associated medical conditions among toxoplasmosis deaths in the United States, 2000-2010Severe acute disseminated toxoplasmosis acquired by an immunocompetent patient in French Guiana.AIDS related opportunistic infections, going but not gone.Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature.In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondiiPyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii.
P2860
Q22305913-5FEB71B7-70C8-4DE1-8B81-F87CF2DE5D57Q22305931-9223D489-AB7A-41FD-A4C7-F54E7D629110Q24245334-F5A50F51-A202-47B8-AAD4-6160519C8A38Q24519019-2879146F-69EB-49AC-A92D-045BC4A7EAE1Q26999453-FE42043A-4EFE-40FE-AAAE-68862EE45251Q27622365-C24D5ACF-ABF2-4182-B899-6D1CB390FDAAQ27661190-EE5C2BE4-EC25-435A-B7CD-3C9C221ECDA0Q27733464-9C78AA0A-D290-4AFC-819F-691470895FC7Q28343549-54AAFE5F-D762-4432-9180-B469CCA63FB4Q28369142-6FB33391-51A5-49D5-B798-DBF1703E0974Q28378281-DD20FE49-64A1-451D-8D67-E5D0ED78E149Q28378877-F2B914CD-35E8-4D0F-9483-ECEF6FD2CA0FQ28379020-1C1336D3-891D-4C4F-B991-8D2DA700C80BQ28748825-99802EDC-23BD-4505-95D5-676772930151Q30417052-B845494C-21E2-4868-A26B-9112DB4ED7A6Q30427210-F81E8B1F-ED96-411F-A749-FA0709D9991AQ30487158-E31213E9-DCD2-4DCF-A47F-C93B0EAA1F11Q31156617-0EC67B95-F3E1-491C-A0D5-55C1C14E8A86Q33418764-FF008C0F-080F-4DD1-9487-1EFFBAF0E4F7Q33606893-D9A433CB-281C-4E7E-B8DD-9AC977CECD96Q33607251-167DB0D8-4CE0-463A-A9AC-20002BECBA6BQ33631447-468CD1E8-127C-4D96-A000-3AFD4D898400Q33650105-239C55D3-B503-4313-9361-DB30388824E6Q33702049-44383A20-96B8-4D02-85D8-48C41998132EQ33746997-ECC6B0F0-4AA7-445D-B921-DDEE3B7BFB18Q33979823-2C36A192-DA15-465E-A668-E0ECE13F7E9AQ33981972-5AF52FFE-FB20-4EE0-94EA-43D637CBE0FBQ34002460-FBB1AEC8-7214-4B33-A747-DE8DDFC4390DQ34105538-B51F33F5-421C-46B3-B931-B8C72DD6939BQ34107885-AC78AABE-32E3-44A9-982F-61D7AA252DB7Q34110618-402A8063-9EB4-4466-9D15-5F6AC53F1664Q34212799-8FF57B1F-7C6B-4E13-B189-0F810E8999A6Q34432386-B803C4CB-8577-47C6-A6F6-231CB562C55DQ34469041-5ED1BC75-DDA8-4B0C-9F05-7F87A799BE20Q34496239-EC75AAA3-3275-42FD-AD27-2A87737D952DQ34685813-FFE987D4-A864-4687-BE10-94C1E76973F9Q34756259-F6D39125-9DB6-470A-9C9C-CDEB3C9F05BBQ34785634-E59FF9A4-8827-4DFE-A3A1-D695E3F85C7DQ35116242-A28C6CCA-1866-442A-ADB1-A2FF43F6A586Q35124802-5323C97E-41B7-47AB-868D-BBDA95079D3A
P2860
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Treatment of toxoplasmic encep ...... Collaborative Treatment Group.
@en
type
label
Treatment of toxoplasmic encep ...... Collaborative Treatment Group.
@en
prefLabel
Treatment of toxoplasmic encep ...... Collaborative Treatment Group.
@en
P2093
P921
P1476
Treatment of toxoplasmic encep ...... Collaborative Treatment Group.
@en
P2093
Antoniskis D
Dannemann B
Israelski D
McCutchan JA
Nussbaum J
P356
10.7326/0003-4819-116-1-33
P407
P577
1992-01-01T00:00:00Z